Budget Impact Flashcards
1
Q
Economic Considerations
A
FDA approved drugs: economic eval (CEA, CUA, etc.), budget impact (health system), financial models (drug costs)
-Yet to be approved drugs
2
Q
Budget Impact Models
A
- Measure of resource use
- Do NOT consider HRQoL
- Time Frame/Perspective: HCDM is recommended, typically time frame is 1-5 years
- Population: target population for a budget impact model
3
Q
Considerations for Budget Impact Models
A
- Characteristics of a health system, like prevalence and incidence
- Use and cost of current mix of therapies used to treat the condition
- Projected use and costs of the new mix of therapies to treat the condition
- Costs and cost offsets associated with change in use of condition-specific health services
4
Q
Budget Impact Models Components
A
- Should include all aspects of health care system
- Main focus is looking at clinical-related outcomes, not patient outcomes. Can include analyses related to QALYs but payers will want to focus on resource-related outcomes
- Should consider realistic estimates of drug uptake
- Will need to include sensitivity analyses for key assumptions
5
Q
Budget Impact Analyses Steps
A
- Health plan demographics, disease epidemiology
- Medication cost for treatment
- Reduction in other treatments?
- Reduce use of other costly utilization?
- Add up costs and savings
- Sensitivity Analyses
6
Q
BIA Step 1
A
members * % with condition * % being treated
7
Q
BIA Step 2
A
- Daily/Monthly Treatment Costs
- Average length of treatment
- # members * cost * duration * adherence
8
Q
BIA Step 3
A
- Will new medication reduce the need for other drugs
- Potential savings
9
Q
BIA Step 4
A
- Reduction of doctor/ER visits, hospitalizations
- # members * difference in % * Cost
- Potential savings
10
Q
BIA Step 5
A
- Add up costs and savings
- Subtract savings from costs
- Divide total cost by total number of members for cost per year
- Divide cost per year by 12 months to get costs per month
11
Q
BIA Step 6
A
- Sensitivity analyses that consider PMPM
- Vary all estimates in model: treated population, medication costs, avoided AE
- Ultimately up to P&T committee to decide if the medication is worth it by using management strategies